Clinical Trial

EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Protocol Amendment History 3 changes
notable Trial sites expanded: 6 -> 58 locations 2026-08-06
critical Recruitment opened 2026-04-17
notable Trial sites expanded: 2 -> 5 locations 2026-04-17
Trial Details
NCT Number NCT07287670
Lead Sponsor Mediar Therapeutics
Conditions Diffuse Cutaneous Systemic Sclerosis
Enrollment 85 participants
Start Date 2026-04-16
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-05